Screening assay for human tumor-associated antigen eliciting specific rejection immunity using human immunized mice
| Project/Area Number |
26830110
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
CUI LIN 九州大学, 先端融合医療レドックスナビ研究拠点, 特任助教 (30717822)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | DNAワクチン / 腫瘍関連抗原遺伝子 / 免疫系ヒト化マウス |
|---|
| Outline of Final Research Achievements |
We have established human immunized mice model by implantation of human peripheral blood mononuclear cells after total irradiation in immunodeficient NOD/SCID/JAK3 null mice, which exhibits a chimera state with predominant human and minor mouse immune cells. We have also established the human immunized mice harboring human biliary tract cancer. We constructed the open-reading frames of several tumor-associated antigen genes as TAA-expression plasmids, and formed DNA vaccine encapsulating the TAA and adjuvant (GM-CSF and CD40L) expression plasmids with nano-sized block/homo-polymer micelles. In the human immunized mice with biliary tract cancer, DNA vaccine expressing TAA-X and adjuvant genes exhibited a significant therapeutic effect. We are on going to identify the mechanism for the induction of TAA-X-specific rejection immunity.
|
Report
(3 results)
Research Products
(9 results)
